Compare ADMA Biologics Inc (ADMA) vs Campbell Soup Co. (CPB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Campbell Soup Co. — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.22B), while Campbell Soup Co. trades at $22.7 (market cap $6.78B). The key difference: Campbell Soup Co. is far larger — about 3.1× ADMA Biologics Inc's market cap, and Campbell Soup Co. pays a 6.87% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | CPB | |
|---|---|---|
Market Cap | $2.22B | $6.78B |
Sector | Health | Consumer Staples |
52-Week High | $20.38 | $34.03 |
52-Week Low | $7.60 | $20.00 |
Enterprise Value | $2.29B | $13.38B |
Dividend Yield | — | 6.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.78, up 0.31% today, with a bullish technical signal from moving averages and strong fundamentals including a 32.98% net income margin and 41.9% ROE. Recent earnings show a mix of beats and misses, with Q3 2026 EPS expected at $0.19. The stock faces headwinds from multiple class-action lawsuits alleging securities fraud, as reported by news outlets in August 2026.
Outlook is cautiously optimistic due to robust profitability and analyst support, but legal risks and recent earnings volatility pose challenges. Investment opportunity hinges on legal resolution and sustained earnings growth, with risks including litigation outcomes and competitive pressures in the biologics sector.
Campbell's (CPB) trades at $22.61, up 0.85% with a bullish technical signal. The company shows stable revenue around $10B but faces margin pressure with net income margin at 6.12%. Recent earnings have been mixed with Q2 2026 results pending. Valuation appears reasonable with P/E of 11.14 and P/S of 0.68. The stock offers a dividend yield around 7%, supported by ongoing product innovation including new protein soups and gluten-free options.
CPB presents a value opportunity with attractive dividend yield but faces execution risks amid margin challenges. Analyst consensus remains cautious with 58.6% hold ratings. The key catalyst is successful implementation of cost-saving initiatives and portfolio rebalancing to improve profitability. Near-term performance depends on Q2 earnings results and consumer spending trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →
